M&A

After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
Motley Fool
Thu, 12/12/19 - 05:25 pm
Celgene
M&A
Bristol-Myers Squibb
Amneal to buy generic pharmaceuticals provider AvKARE for $340m
Pharmaceutical Business Review
Wed, 12/11/19 - 09:54 pm
Amneal
generics
M&A
AvKARE
2 Top Biotech Buyout Candidates
Motley Fool
Wed, 12/11/19 - 10:38 am
M&A
Amarin
Vascepa
Aurinia Pharmaceuticals
voclosporin
Justice Department Will Reportedly Review Google’s $2.1 Billion Fitbit Acquisition
Forbes
Wed, 12/11/19 - 10:09 am
DOJ
Google
Fitbit
wearables
devices
M&A
For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans
Biopharma Dive
Tue, 12/10/19 - 11:51 pm
M&A
Gilead Sciences
Kite
Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both
Motley Fool
Tue, 12/10/19 - 11:48 pm
Sanofi
immuno-oncology
M&A
Synthorx
Roche extends tender offer for Spark Therapeutics, again
Marketwatch
Mon, 12/9/19 - 11:42 pm
Roche
Spark Therapeutics
M&A
Disruptor of the Year: The Federal Trade Commission
Biopharma Dive
Mon, 12/9/19 - 11:16 pm
FTC
M&A
Roche
Spark Therapeutics
Merck to acquire ArQule for $20 per share in cash or about $2.7 billion
Marketwatch
Mon, 12/9/19 - 10:06 am
Merck
M&A
Arqule
oncology
Deal of the Year: Bristol-Myers Squibb buys Celgene
Biopharma Dive
Mon, 12/9/19 - 09:51 am
M&A
Bristol-Myers Squibb
Celgene
Sanofi to acquire Synthorx for $2.5 billion
Marketwatch
Mon, 12/9/19 - 09:27 am
Sanofi
M&A
Synthorx
Alexion shoots down 'proactive' sale demand from activist investor
Fierce Pharma
Fri, 12/6/19 - 10:42 am
Alexion
investors
M&A
Why Sorrento Therapeutics Was Right to Reject Takeover Bids With A 245% Premium
Motley Fool
Thu, 12/5/19 - 11:29 pm
Sorrento Therapeutics
M&A
ZTlido
Lilly puts its cancer future in Loxo's hands
Biopharma Dive
Thu, 12/5/19 - 10:20 am
Eli Lilly
Loxo Oncology
M&A
cancer
R&D
oncology
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Yahoo/Bloomberg
Wed, 12/4/19 - 10:02 am
gene therapy
Astellas
Audentes Therapeutics
M&A
Novartis
Medicines Company
Is Clovis Oncology Really a Buyout Candidate?
Motley Fool
Tue, 12/3/19 - 10:21 pm
Clovis Oncology
M&A
Rubraca
oncology
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Motley Fool
Mon, 12/2/19 - 11:59 pm
Novartis
Medicines Company
M&A
inclisiran
Japan's Astellas to buy Audentes for $3 billion in gene therapy push
Reuters
Mon, 12/2/19 - 11:58 pm
Astellas
M&A
gene therapy
Audentes Therapeutics
Veloxis wins $1.3B buyout deal, and the new owner plans to follow up with new deals
Endpoints
Tue, 11/26/19 - 09:47 am
Asahi Kasei
Veloxis Pharmaceuticals
M&A
organ rejection
Envarsus XR
kidney transplants
Why Novartis Is Buying The Medicines Company For $9.7 Billion
Forbes
Tue, 11/26/19 - 09:44 am
Novartis
Medicines Company
M&A
inclisiran

Pages